RT Journal Article
SR Electronic
T1 Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.26.20044222
DO 10.1101/2020.03.26.20044222
A1 An, Jianghong
A1 Liao, Xuejiao
A1 Xiao, Tongyang
A1 Qian, Shen
A1 Yuan, Jing
A1 Ye, Haocheng
A1 Qi, Furong
A1 Shen, Chengguang
A1 Liu, Yang
A1 Wang, Lifei
A1 Cheng, Xiaoya
A1 Li, Na
A1 Cai, Qingxian
A1 Wang, Fang
A1 Chen, Jun
A1 Liu, Yingxia
A1 Wang, Yunfang
A1 Zhang, Feng
A1 Fu, Yang
A1 Tan, Xiaohua
A1 Liu, Lei
A1 Zhang, Zheng
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.26.20044222.abstract
AB Background It has been reported that several cases recovered from COVID-19 tested positive for SARS-CoV-2 after discharge (re-detectable positive, RP), however the clinical characteristics, significance and potential cause of RP patients remained elusive.Methods A total of 262 COVID-19 patients were discharged from January 23 to February 25, 2020, and were enrolled for analysis of their clinical parameters. The RP and non-RP (NRP) patients were grouped according to the disease severity during their hospitalization period. The clinical characterization at re-admission to the hospital was analyzed. SARS-CoV-2 RNA and plasma antibody levels were detected using high-sensitive detection methods.Findings Up to March 10, 2020, all of patients were followed up for at least 14 days, and 38/262 of RP patients (14.5%) were present. The RP patients were characterized by being less than 14-years old and having mild and moderate conditions as compared to NRP patients, while no severe patients became RP. Retrospectively, the RP patients displayed fewer symptoms, more sustained remission of CT imaging and earlier RNA negative-conversion but similar plasma antibody levels during their hospitalization period as compared to those NRP patients. When re-admitted to the hospital, these RP patients showed no obvious clinical symptoms or disease progression indicated by normal or improving CT imaging and inflammatory cytokine levels. All 21 close contacts of RP patients were tested negative for SARS-CoV-2 RNA, and no suspicious clinical symptoms were reported. However, 18/24 of RNA-negative samples detected by the commercial kit were tested to be positive for virus RNA using a hyper-sensitive method, suggesting the carrier status of virus possibly existed in patients recovered from COVID-19.Interpretation Our results showed that young and mild COVID-19 patients seem to be RP patients after discharge, who show no obviously clinical symptoms and disease progression upon re-admission. More sensitive RNA detection methods are required to monitor these patients during follow-up. Our findings provide empirical information and evidence for the effective management of COVID-19 patients during their convalescent phase.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI have full access to all the data in the study and had final responsibility for the decision to submit for publication.